The Synergistic In Vitro And In Vivo Antitumor Effect Of Combination Therapy With Salinomycin And 5-Fluorouracil Against Hepatocellular Carcinoma
Fan Wang,Weiqi Dai,Yugang Wang,Miao Shen,Kan Chen,Ping Cheng,Yan Zhang,Chengfen Wang,Jingjing Li,Yuanyuan Zheng,Jie Lu,Jing Yang,Rong Zhu,Huawei Zhang,Yingqun Zhou,Ling Xu,Chuanyong Guo
DOI: https://doi.org/10.1371/journal.pone.0097414
IF: 3.7
2014-01-01
PLoS ONE
Abstract:Hepatocellular carcinoma (HCC) is one of the few cancers in which a continuous increase in incidence has been observed over several years. Drug resistance is a major problem in the treatment of HCC. In the present study, we used salinomycin (Sal) and 5-fluorouracil (5-FU) combination therapy on HCC cell lines Huh7, LM3 and SMMC-7721 and nude mice subcutaneously tumor model to study whether Sal could increase the sensitivity of hepatoma cells to the traditional chemotherapeutic agent such as 5-FU. The combination of Sal and 5-FU resulted in a synergistic antitumor effect against liver tumors both in vitro and in vivo. Sal reversed the 5-FU-induced increase in CD133(+) EPCAM(+) cells, epithelial-mesenchymal transition and activation of the Wnt/beta-catenin signaling pathway. The combination of Sal and 5-FU may provide us with a new approach to reverse drug resistant for the treatment of patients with HCC.